Výsledky vyhledávání - "Nahoko Yamashita"

Akademický článek

Nutrient Condition in the Microenvironment Determines Essential Metabolisms of CD8+ T Cells for Enhanced IFNγ Production by Metformin

Autor: Ruoyu Chao, Mikako Nishida, Nahoko Yamashita, Miho Tokumasu, Weiyang Zhao, Ikuru Kudo, Heiichiro Udono

Publikováno v: Frontiers in Immunology, Vol 13 (2022)

Metformin (Met), a first-line drug for type 2 diabetes, lowers blood glucose levels by suppressing gluconeogenesis in the liver, presumably through the liver kinase B1-dependent activation of AMP-activated protein kinase (AMPK) after inhibiting respi

Externí odkaz: https://doaj.org/article/52de732c455f4df9b63e080764607d99

Zobrazit plný text záznamu

Akademický článek

Mitochondrial reactive oxygen species trigger metformin-dependent antitumor immunity via activation of Nrf2/mTORC1/p62 axis in tumor-infiltrating CD8T lymphocytes

Autor: Kazuhiro Kakimi, Hirokazu Matsushita, Masaaki Komatsu, Eiryo Kawakami, Mikako Nishida, Nahoko Yamashita, Taisaku Ogawa, Keita Koseki, Eiji Warabi, Tomoyuki Ohue, Katsuyuki Shiroguchi, Heiichiro Udono

Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 9, Iss 9 (2021)

Externí odkaz: https://doaj.org/article/ea6e95b1875f4efea28894d8d086bffc

Zobrazit plný text záznamu

Akademický článek

Metformin synergizes with PD-1 blockade to promote normalization of tumor vessels via CD8T cells and IFNγ.

Autor: Miho Tokumasu, Mikako Nishida, Weiyang Zhao, Ruoyu Chao, Natsumi Imano, Nahoko Yamashita, Kyoko Hida, Hisamichi Naito, Heiichiro Udono

Publikováno v: Proceedings of the National Academy of Sciences of the United States of America; 7/23/2024, Vol. 121 Issue 30, p1-8, 8p

Zobrazit plný text záznamu

Nutrient Condition in the Microenvironment Determines Essential Metabolisms of CD8(+) T Cells for Enhanced IFN gamma Production by Metformin

Autor: Ruoyu Chao, Mikako Nishida, Nahoko Yamashita, Miho Tokumasu, Weiyang Zhao, Ikuru Kudo, Heiichiro Udono

Publikováno v: Frontiers In Immunology. 13:864225

Metformin (Met), a first-line drug for type 2 diabetes, lowers blood glucose levels by suppressing gluconeogenesis in the liver, presumably through the liver kinase B1-dependent activation of AMP-activated protein kinase (AMPK) after inhibiting respi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b1ca8c37e8fe7060f106ecd6c23720b3
https://ousar.lib.okayama-u.ac.jp/63798

Zobrazit plný text záznamu